Validation of adherence prediction system for lifestyle interventions in nonalcoholic fatty liver disease
- PMID: 38855158
- PMCID: PMC11154672
- DOI: 10.3748/wjg.v30.i20.2629
Validation of adherence prediction system for lifestyle interventions in nonalcoholic fatty liver disease
Abstract
This editorial delves into the research article by Zeng et al published in the latest issue of World Journal of Gastroenterology. The manuscript contributes significantly to addressing the global health issue of nonalcoholic fatty liver disease (NAFLD) by introducing and validating the Exercise and Diet Adherence Scale (EDAS). The article effectively conveys the importance of the study, highlighting the prevalence of NAFLD, the lack of approved drugs for its treatment, and the crucial role of lifestyle correction. The use of the Delphi method for scale deve-lopment and the subsequent evaluation of its reliability add scientific rigor to the methodology. The results demonstrate that the scale is correlated with key lifestyle indicators, which makes it a promising tool for assessing patient adherence to interventions. The identification of specific score thresholds for predicting adherence to daily calorie intake and exercise adds practical value to the scale. The differentiation among scores indicative of good, average, and poor adherence enhances its clinical applicability. In conclusion, the manuscript introduces EDAS, a valuable instrument that can contribute substantially to the field of NAFLD research and clinical practice.
Keywords: Adherence assessment; Delphi method; Exercise and Diet Adherence Scale; Lifestyle interventions; Nonalcoholic fatty liver disease.
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: Dr. Chisthi has nothing to disclose.
Similar articles
-
Establishment and validation of an adherence prediction system for lifestyle interventions in non-alcoholic fatty liver disease.World J Gastroenterol. 2024 Mar 14;30(10):1393-1404. doi: 10.3748/wjg.v30.i10.1393. World J Gastroenterol. 2024. PMID: 38596499 Free PMC article.
-
Quantitative assessment of self-management in patients with non-alcoholic fatty liver disease: An unmet clinical need.World J Gastroenterol. 2024 Jul 7;30(25):3143-3146. doi: 10.3748/wjg.v30.i25.3143. World J Gastroenterol. 2024. PMID: 39006382 Free PMC article.
-
Scale offers the possibility of identifying adherence to lifestyle interventions in patients with non-alcoholic fatty liver disease.World J Gastroenterol. 2024 Jul 7;30(25):3179-3181. doi: 10.3748/wjg.v30.i25.3179. World J Gastroenterol. 2024. PMID: 39006387 Free PMC article.
-
Effective roles of exercise and diet adherence in non-alcoholic fatty liver disease.World J Gastroenterol. 2024 Aug 7;30(29):3456-3460. doi: 10.3748/wjg.v30.i29.3456. World J Gastroenterol. 2024. PMID: 39156504 Free PMC article. Review.
-
Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.Z Gastroenterol. 2019 Apr;57(4):508-517. doi: 10.1055/a-0784-8827. Epub 2019 Apr 9. Z Gastroenterol. 2019. PMID: 30965381 Review. English.
Cited by
-
Mediating Role of Lipid Accumulation Products (LAP) in the Association of WBC with MASLD: SWH 2021-2023.J Inflamm Res. 2025 Aug 11;18:10845-10854. doi: 10.2147/JIR.S539627. eCollection 2025. J Inflamm Res. 2025. PMID: 40823349 Free PMC article.
References
-
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. - PubMed
-
- Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357. - PubMed
-
- Dongiovanni P, Lanti C, Riso P, Valenti L. Nutritional therapy for nonalcoholic fatty liver disease. J Nutr Biochem. 2016;29:1–11. - PubMed
-
- McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148–1155. - PubMed
-
- Naik A, Košir R, Rozman D. Genomic aspects of NAFLD pathogenesis. Genomics. 2013;102:84–95. - PubMed